Toll-like receptor signaling pathway in chronic lymphocytic leukemia: Distinct gene expression profiles of potential pathogenic significance in specific subsets of patients

Haematologica

Volumn 96, Issue 11, 2011, Pages 1644-1652

  Arvaniti, Eleni ^a,b   Ntoufa, Stavroula ^a,c   Papakonstantinou, Nikos ^c   Touloumenidou, Tasoula ^c   Laoutaris, Nikolaos ^b   Anagnostopoulos, Achilles ^c   Lamnissou, Klea ^a   Caligaris Cappio, Federico ^d,e   Stamatopoulos, Kostas ^c,f   Ghia, Paolo ^d,e   Muzio, Marta ^d   Belessi, Chrysoula ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b Nikea General Hospital Athens   (Greece)

^c G PAPANICOLAOU HOSPITAL   (Greece)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

Author keywords

Chronic lymphocytic leukemia; Gene expression profiling; Signaling pathway; Toll like receptor

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD180 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERLEUKIN 6; LYMPHOCYTE ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CD180 GENE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN CELL; IL6 GENE; IMMUNOGLOBULIN HEAVY CHAIN GENE; IRF GENE; JNK GENE; MAJOR CLINICAL STUDY; MAPK GENE; NF GENE; NFKB GENE; OVERALL SURVIVAL; P38 GENE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TLR1 GENE; TLR10 GENE; TLR2 GENE; TLR6 GENE; TLR7 GENE; TLR9 GENE;

B-LYMPHOCYTES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MAP KINASE SIGNALING SYSTEM; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TOLL-LIKE RECEPTORS;

EID: 80355126549     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.044792     Document Type: Article

References (49)

1. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008; 26(27):4497-503.
2. Damle RN, Calissano C, Chiorazzi N. Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol. 2010;23(1):33-45.
3. Darzentas N, Hadzidimitriou A, Murray F, Hatzi K, Josefsson P, Laoutaris N, et al. A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia. 2010;24(1):125-32.
4. Rosen A, Murray F, Evaldsson C, Rosenquist R. Antigens in chronic lymphocytic leukemia-implications for cell origin and leukemogenesis. Semin Cancer Biol. 2010;20(6):400-6.
5. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell. 1997;91(3):295-8.
6. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21: 335-76.
7. Kawai T, Akira S. The role of pattern recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2001; 11(5):373-84.
8. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2(8):675-80.
9. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect. 2004;6(15):1382-7.
10. Crampton SP, Voynova E, Bolland S. Innate pathways to B-cell activation and tolerance. Ann NY Acad Sci. 2010;1183:58-68.
11. Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol 2005;17(3): 230-6.
12. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003;101(11):4500-4.
13. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood. 2003;102(3):956-63.
14. Dasari P, Nicholson IC, Hodge G, Dandie GW, Zola H. Expression of toll-like receptors on B lymphocytes. Cell Immunol. 2005;236(1,2):140-5.
15. Pone EJ, Zan H, Zhang J, Al-Qahtani A, Xu Z, Casali P. Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: rele vance to microbial antibody responses. Crit Rev Immunol. 2010;30(1):1-29.
16. Carmody RJ, Chen YH. Nuclear factorkappa B: activation and regulation during toll-like receptor signaling. Cell Mol Immunol. 2007;4(1):31-41.
17. Park SR, Zan H, Pal Z, Zhang J, Al-Qahtani A, Pone EJ, et al. HoxC4 binds to the promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA recombination and somatic hypermutation. Nat Immunol. 2009;10(5):540-50.
18. Chaturvedi A, Pierce SK. How location governs toll-like receptor signaling. Traffic. 2009;10(6):621-8.
19. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak- Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and toll-like receptors. Nature. 2002;486 (6881):603-7.
20. Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9-ligand stimulates B-cell proliferation and antigenspecific plasma cell formation. Blood. 2009;113(17):3969-77.
21. Meyer-Bahlburg A, Rawlings DJ. B cell autonomous TLR signaling and autoimmunity. Autoimmun Rev. 2008;7(4):313-6.
22. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol. 2006;36(4):810-6.
23. Poovassery JS, Vanden Bush TJ, Bishop GA. Antigen receptor signals rescue B cells from TLR tolerance. J Immunol. 2009;183(5): 2974-83.
24. Spaner DE, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia. 2007;21(1): 53-60.
25. Grandjenette C, Kennel A, Faure GC, Béné MC FP. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica. 2007;92(9): 1279-81.
26. Rozková D, Novotná L, Pytlík R, Hochová I, Kozák T, Bartůnková J, et al. Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int J Cancer. 2010;126(5):1132-43.
27. Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2009;144(4):507-16.
28. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111 (12):5446-56.
29. Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109(1):259-70.
30. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized andintegrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008;36(Web Server issue):W503-W8.
31. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009;37(Database issue):D1006-12.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402-8.
33. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood. 2000; 95(3):999-1006.
34. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR, et al. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood. 2010;115(24):5041-52.
35. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2007;21(1):110-20.
36. Spaner DE, Shi Y, White D, Mena J, Hammond C, Tomic J, et al. Immunomodulatory effects of Toll-like receptor-7 activation on CLL cells. Leukemia. 2006;20(2):286-95.
37. Shi Y, White D, He L, Miller RL, Spaner DE. Toll-like receptor-7 tolerizes malignant B cells and enhances klling by cytotoxic agents. Cancer Res. 2007;67(4):1823-31.
38. Hammadi A, Billard C, Faussat AM, Kolb JP. Resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kB activation. Nitric Oxide. 2008;19: 138-45.
39. Porakishvili N, Kulikova N, Jewell AP, Youinou PY, Yong K, Nathwani A, et al. Differential expression of CD180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br J Haematol. 2005;131(3):313-9.
40. Tiscornia AC, Cayota A, Landon AI, Brito C, Oppezzo P, Vuillier F, et al. Post- transcriptional regulation of inducible nitric oxide synthase in chronic lymphocytic leukemia B cells in pro- and antiapoptotic culture conditions. Leukemia. 2004;18(1): 48-56.
41. Chiotoglou I, Smilevska T, Samara M, Likousi S, Belessi C, Athanasiadou I, et al. Predominantly post-transcriptional regulation of activation molecules in chronic lymphocytic leukemia: the case of transferrin receptors. Blood Cells Mol Dis. 2008; 41(2):203-9.
42. Chu CC, Catera R, Zhang L, Didier S, Agagnina BM, Damle RN, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood. 2010;115(19):3907-15.
43. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194(11):1625-38.
44. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194(11):1639-47.
45. Van den Hove LE, Van Gool SW, Vandenberghe P, Bakkus M, Thielemans K, Boogaerts MA, et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia. 1997;11(4): 572-80.
46. Marincevic M, Mansouri M, Kanduri M, Isaksson A, Göransson H, Smedby KE, et al. Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. Haematologica. 2010;95(12): 2072-9.
47. Marincevic M, Cahill N, Gunnarsson R, Isaksson A, Mansouri M, Göransson H, et al. High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4- 34 B-cell receptors. Haematologica. 2010;95(9):1519-25.
48. Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: therole of antigen stimulation. J Intern Med. 2008;264(6):549- 62.
49. Lanemo Myhrinder A, Hellqvist E, Sidorova E, Söderberg A, Baxendale H, Dahle C, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008; 111(7):3838-48.